EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan

Abstract

Authors

M. Yamaguchi T. Maeda K. Morimoto W. Chen K. Moriwaki K. Shimozuma

Full Text Cite This Article
Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×